1.2200
22-November-24 15:44:58
15 minutes delayed
Stocks
+0.0300
+2.52%
Today's range
1.1700 - 1.2300
ISIN
N/A
Source
NASDAQ
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
12 Jun 2023 08:15:00 By Nasdaq GlobeNewswire
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
01 Jun 2023 08:10:00 By Nasdaq GlobeNewswire